FDA issues a new draft guidance on the application of the benefit-risk assessment framework for evaluating applications for opioids.
Statement on the FDA’s benefit-risk framework for evaluating opioid analgesics
More from FDA News AlertsMore posts in FDA News Alerts »
- Coronavirus (COVID-19) Update: June 22, 2021
- Prairie Wolf Spirits, Inc. Issues Voluntary Nationwide Recall of Prairie Wolf Distillery Hand Sanitizer Packed in 16.9 Oz. and 20 Oz Bottles Because They Resemble Drink Containers
- Sanit Technologies Adds Label Clarification to Existing Voluntary Hand Sanitizer Recall
- FDA Approves First Oral Blood Thinning Medication for Children